Ozempic, Wegovy among drugs subject to Medicare price controls

Published On Jan 17, 2025, 11:29 AM

The article discusses the recent decision by Medicare to impose price controls on several drugs, including Novo Nordisk's Ozempic and Wegovy, as part of the Inflation Reduction Act. These price controls are intended to reduce costs for Medicare beneficiaries but have faced backlash from pharmaceutical companies, including Novo Nordisk, which argue that such regulations could hinder patient access to medications and discourage future drug development. The price controls are set to take effect in 2027.